Unison Asset Management LLC Grows Position in Elevance Health, Inc. $ELV

Unison Asset Management LLC grew its position in Elevance Health, Inc. (NYSE:ELV) by 7.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,745 shares of the company’s stock after purchasing an additional 1,824 shares during the quarter. Elevance Health makes up approximately 4.3% of Unison Asset Management LLC’s portfolio, making the stock its 7th largest holding. Unison Asset Management LLC’s holdings in Elevance Health were worth $9,704,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Physician Wealth Advisors Inc. increased its position in Elevance Health by 331.6% during the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after acquiring an additional 63 shares during the period. Rossby Financial LCC increased its position in Elevance Health by 110.0% during the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after acquiring an additional 44 shares during the period. Activest Wealth Management increased its position in Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after acquiring an additional 34 shares during the period. ORG Partners LLC increased its position in Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after acquiring an additional 59 shares during the period. Finally, Dorato Capital Management bought a new position in Elevance Health during the fourth quarter worth $41,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Down 1.7%

Shares of Elevance Health stock opened at $387.83 on Wednesday. The firm has a market capitalization of $84.22 billion, a PE ratio of 16.50, a price-to-earnings-growth ratio of 2.23 and a beta of 0.66. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The company’s fifty day moving average price is $337.85 and its two-hundred day moving average price is $337.45. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $408.00.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. During the same quarter in the previous year, the firm posted $11.97 EPS. The business’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, analysts expect that Elevance Health, Inc. will post 26.91 EPS for the current year.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s payout ratio is currently 29.26%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ELV. Guggenheim boosted their target price on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Robert W. Baird boosted their target price on shares of Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research report on Thursday, April 23rd. Wells Fargo & Company lowered their price target on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a report on Friday, January 30th. Jefferies Financial Group lowered their price target on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Finally, Citigroup raised shares of Elevance Health to a “buy” rating in a report on Wednesday, April 29th. Fourteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $403.11.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.